Skip to main content
  • Register
  • Help
  • Contact us

Sana Biotechnology Inc (SANA) USD0.0001

Sell:$25.64 Buy:$25.74 Change: $1.59 (6.60%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.59 (6.60%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.59 (6.60%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sana Biotechnology, Inc is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. It focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

Contact details

188 East Blaine Street
Suit 400, Suite 400
United States
+1 (206) 7017914

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$4.36 billion
Shares in issue:
187.51 million
United States
US dollar

Key personnel

  • Hans Bishop
    Executive Chairman of the Board
  • Steven Harr
    President, Chief Executive Officer, Director
  • Nate Hardy
    Chief Financial Officer, Senior Vice President
  • Robin Andrulevich
    Chief Human Resource Officer, Chief People Officer
  • Edward Rebar
    Senior Vice President, Chief Technology Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.